Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Treasury Shares: 2014-2025

Historic Treasury Shares for Theravance Biopharma (TBPH) over the last 8 years, with Sep 2025 value amounting to $3.7 million.

  • Theravance Biopharma's Treasury Shares fell 12.73% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 12.73%. This contributed to the annual value of $4.0 million for FY2024, which is 1.01% down from last year.
  • Theravance Biopharma's Treasury Shares amounted to $3.7 million in Q3 2025, which was down 8.88% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Treasury Shares ranged from a high of $15.6 million in Q3 2023 and a low of $3.1 million during Q1 2024.
  • In the last 3 years, Theravance Biopharma's Treasury Shares had a median value of $4.3 million in 2024 and averaged $5.9 million.
  • In the last 5 years, Theravance Biopharma's Treasury Shares spiked by 67.28% in 2021 and then crashed by 72.59% in 2024.
  • Over the past 5 years, Theravance Biopharma's Treasury Shares (Quarterly) stood at $8.4 million in 2021, then surged by 52.49% to $12.7 million in 2022, then slumped by 68.63% to $4.0 million in 2023, then fell by 1.01% to $4.0 million in 2024, then dropped by 12.73% to $3.7 million in 2025.
  • Its Treasury Shares stands at $3.7 million for Q3 2025, versus $4.1 million for Q2 2025 and $4.5 million for Q1 2025.